Expertise in
13
conditions

Dr. Elizabeth Henry

Hematology
Dept. Of Veterans Affairs
5000 S 5th Ave, 
Hines, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
13
conditions
Dept. Of Veterans Affairs
5000 S 5th Ave, 
Hines, IL 

Overview

Elizabeth Henry is a Hematologist in Hines, Illinois. Dr. Henry is highly rated in 13 conditions, according to our data. Her top areas of expertise are Prostate Cancer, WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Bone Marrow Aspiration, and Gastrostomy.

Her clinical research consists of co-authoring 14 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in IL

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Dept. of Veterans Affairs
5000 S 5th Ave, Hines, IL 60141

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Enrollment Status: Recruiting
Publish Date: September 11, 2025
Intervention Type: Procedure, Drug, Other, Radiation
Study Drugs: Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin acetate, Histrelin acetate, Leuprolide acetate, Nilutamide, Prednisone, Triptorelin
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
A Phase I/II Study of Salvage High-dose-rate Brachytherapy, ExternAl Beam COmbined and Short-term Hormonal Therapy for the Treatment of Node-positive Locally Recurrent Prostate Cancer After Prior Definitive Radiotherapy
A Phase I/II Study of Salvage High-dose-rate Brachytherapy, ExternAl Beam COmbined and Short-term Hormonal Therapy for the Treatment of Node-positive Locally Recurrent Prostate Cancer After Prior Definitive Radiotherapy
Enrollment Status: Terminated
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drug: ADT
Study Phase: Phase 1/Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
A Sero-Epidemiologic Survey and Cost Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients
A Sero-Epidemiologic Survey and Cost Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients
Enrollment Status: Completed
Publish Date: July 03, 2023
A Phase II Study Examining the Use of Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed Acute Myelogenous Leukemia (AML) in Elderly Patients
A Phase II Study Examining the Use of Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed Acute Myelogenous Leukemia (AML) in Elderly Patients
Enrollment Status: Terminated
Publish Date: February 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

14 Total Publications

Likes and Hashtags: Exploring the Potential Relationship Between Social Media Use and the Emotional Wellbeing of Oncology Professionals.
Likes and Hashtags: Exploring the Potential Relationship Between Social Media Use and the Emotional Wellbeing of Oncology Professionals.
Journal: Pediatric blood & cancer
Published: November 14, 2024
Similar Doctors
Leo I. Gordon
Expertise in
33
conditions
Dr. Leo I. Gordon
Hematology | Oncology
Expertise in
33
conditions
Dr. Leo I. Gordon
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (11.6 miles away)
866-587-4322
Experience:
53+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leo Gordon is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Gordon has been practicing medicine for over 53 years is highly rated in 33 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Rimas V. Lukas
Expertise in
25
conditions
Dr. Rimas V. Lukas
Hematology | Oncology
Expertise in
25
conditions
Dr. Rimas V. Lukas
Hematology | Oncology
675 N St Clair St Ste 20-100, Galter Pavilion, 
Chicago, IL 
 (11.6 miles away)
312-695-4360
Experience:
24+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Rimas Lukas is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Lukas has been practicing medicine for over 24 years is highly rated in 25 conditions, according to our data. His top areas of expertise are Astrocytoma, Glioma, Glioblastoma, Brain Tumor, and Gastrostomy.

Expertise in
12
conditions
Dr. Santosh Saraf
Hematology
Expertise in
12
conditions
Dr. Santosh Saraf
Hematology

University Of Illinois Chicago Physician Group (Uicpg)

1801 W Taylor St, 
Chicago, IL 
 (8.4 miles away)
312-355-1700
Languages Spoken:
English
See accepted insurances

Santosh Saraf is a Hematologist in Chicago, Illinois. Dr. Saraf is highly rated in 12 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Elizabeth Henry

How do I make an appointment with Dr. Elizabeth Henry?

You can book an appointment with Dr. Elizabeth Henry by calling their office at 708-202-8387. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Elizabeth Henry a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Elizabeth Henry is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Elizabeth Henry specialize in?

While Dr. Elizabeth Henry is a Hematology, they have specific expertise in Prostate Cancer, WT1-Related Wilms Tumor Syndromes, and Clear Cell Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Elizabeth Henry participate in research or clinical trials?

Yes. Dr. Elizabeth Henry has published 14 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Elizabeth Henry's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Henry's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 20 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile